Related Experiment Video

Updated: Aug 29, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Growth-stimulating pathways in lung cancer: implications for targets of therapy

I Sekine1, N Saijo

  • 1Internal Medicine and Thoracic Oncology Division, National Cancer Center Hospital, Tokyo, Japan. isekine@gan2.ncc.go.jp

Clinical Lung Cancer
|January 15, 2004
PubMed

Insights

Targeting growth-stimulating pathways is key for lung cancer treatment. Inhibitors of receptor tyrosine kinases show promise for non-small-cell lung cancer, even with distant metastases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Growth-stimulating pathways, independent of normal tissue, drive lung cancer initiation and progression.
  • These pathways involve growth factors, receptors (G-protein-coupled or receptor tyrosine kinases), signal transduction, and nuclear targets.
  • Autocrine and paracrine mechanisms of growth factors promote lung cancer cell expansion.

Purpose of the Study:

  • To review the role of growth-stimulating pathways in lung cancer.
  • To highlight recent advancements in understanding oncoproteins within these pathways.
  • To discuss the therapeutic potential of targeting these pathways, particularly receptor tyrosine kinases.

Main Methods:

  • Review of scientific literature on lung cancer growth pathways.
  • Analysis of signal transduction networks, including Ras, phosphatidylinositol-3-OH kinase, and phospholipase C.
  • Examination of clinical trial data for novel therapeutic agents.

Main Results:

  • Receptor tyrosine kinase inhibitors have shown promising results in Phase I studies.
  • Epidermal growth factor-receptor inhibitors demonstrated objective responses in non-small-cell lung cancer patients.
  • These agents exhibited minimal toxicity as single agents in chemotherapy-refractory patients.

Conclusions:

  • Targeting growth-stimulating pathways offers a novel therapeutic strategy for lung cancer.
  • Receptor tyrosine kinase inhibitors represent a significant advancement, especially for metastatic disease.
  • This approach may lead to breakthroughs in treating lung cancer unresponsive to conventional therapies.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...